-

Betting on a Cure: Jason Colodne and Colbeck Capital Renew Support for Children’s Tumor Foundation Charity Poker Tournament

NEW YORK--(BUSINESS WIRE)--Colbeck Capital Management, a leading middle-market private credit firm focused on strategic lending, today announced its continued support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through sponsorship of its 2026 New York City Charity Poker Tournament. The tournament, to be held June 18 at The Prince George Ballroom, brings supporters together for the Children's Tumor Foundation and features a cocktail reception followed by Texas Hold 'Em tournament play.

Every buy-in, sponsorship, and donation advances the Foundation's work to end neurofibromatosis and schwannomatosis (collectively known as NF), a group of genetic conditions that cause tumors to form on nerves throughout the body. Support from Jason Colodne and Colbeck Capital helps drive research, expand knowledge, and advance care for individuals and families affected by NF.

Founded in 1978, the Children's Tumor Foundation has served as the drug discovery engine for NF, working to put treatments in patients' hands sooner. By uniting doctors, scientists, pharmaceutical partners, and affected families behind a single goal, CTF takes a patient-first, collaborative approach that speeds drug development and brings life-changing therapies to those living with neurofibromatosis and schwannomatosis. To learn more about the event, please click here.

About Colbeck Capital Management
Colbeck Capital Management (colbeck.com) is a leading, middle-market private credit manager focused on strategic lending. Colbeck originates senior secured loans to companies going through periods of transition, providing creative capital solutions. Colbeck sponsors its portfolio companies through consistent engagement with management teams in areas such as finance, capital markets and growth strategies, distinguishing itself from traditional lenders. Colbeck was founded in 2009 by Jason Colodne and Jason Beckman and currently manages $3+ billion of invested and committed capital. Colbeck’s principals have extensive experience investing through different market cycles at leading institutions, including Goldman Sachs and Morgan Stanley.

Contacts

Media Contacts
Jonathan Warren/Jared Kimmel
Gasthalter & Co.
(212) 257-4170
colbeck@gasthalter.com

Colbeck Capital Management


Release Versions

Contacts

Media Contacts
Jonathan Warren/Jared Kimmel
Gasthalter & Co.
(212) 257-4170
colbeck@gasthalter.com

More News From Colbeck Capital Management

Colbeck Capital Launches Strategic Income Vertical with $400 Million

NEW YORK--(BUSINESS WIRE)--Colbeck Capital Management (“Colbeck”), a leading middle-market private credit firm focused on strategic lending, announced the launch of Colbeck Strategic Income (“CSI”), a new direct lending vertical, with an initial capital commitment of approximately $400 million. The launch of CSI demonstrates continued market demand for Colbeck’s differentiated products and complements the firm’s $1.7+ billion Colbeck Strategic Lending ("CSL") vertical.1 CSL closed its third fun...

Colbeck Capital Renews Commitment to the Children's Tumor Foundation in Recognition of World NF Awareness Day

NEW YORK--(BUSINESS WIRE)--Colbeck Capital Management, a leading middle-market private credit firm focused on strategic lending, today announced its continued support for the Children’s Tumor Foundation (“CTF” or the “Foundation”) in recognition of World NF Awareness Day, which brings global attention to neurofibromatosis and schwannomatosis (collectively known as NF), a group of genetic conditions that cause tumors to grow on nerves throughout the body. World NF Awareness Day is observed annua...

Jason Colodne and Colbeck Capital Sponsor the Children's Tumor Foundation 2025 National Gala

NEW YORK--(BUSINESS WIRE)--Colbeck Capital Management (“Colbeck”) today announced support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through sponsorship of the Foundation’s 2025 National Gala. The annual event, to be held November 17 at Gotham Hall in New York City, helps raise important funds to advance research and care developments while celebrating extraordinary progress in NF research and recognizing the individuals and partners driving progress toward ending NF (short...
Back to Newsroom